Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.
- The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.
- Integrase inhibitors, in addition to capsid inhibitors and nucleoside reverse transcriptase inhibitors, are a class of agents under investigation as long-acting antiretroviral therapies.
- Preclinical pharmacokinetic and toxicology studies conducted to date support the development of XVIR-110 as a potential once-yearly antiretroviral therapeutic for HIV treatment and prevention.
- Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiretroviral therapeutics.